Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$0.05 and last traded at C$0.06, with a volume of 5071 shares. The stock had previously closed at C$0.06.
Hemostemix Stock Performance
The company has a market capitalization of C$10.88 million, a P/E ratio of -2.75 and a beta of 0.18. The stock’s 50 day moving average is C$0.06 and its 200-day moving average is C$0.08. The company has a debt-to-equity ratio of -66.09, a current ratio of 0.24 and a quick ratio of 0.48.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Featured Articles
- Five stocks we like better than Hemostemix
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
- 5 High-Yield Stocks With Analyst Support and Room to Run
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
